Recent News

• 09.16.2025 - Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
• 09.09.2025 - Teva’s Emrusolmin Granted U.S. FDA Fast Track Designation for Treatment of Multiple System Atrophy
• 09.02.2025 - Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September
• 08.28.2025 - Teva Announces FDA Approval and Launch of Generic Saxenda® (liraglutide injection) – First Generic GLP-1 Indicated for Weight Loss
• 08.06.2025 - FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
• 07.30.2025 - Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
• 06.26.2025 - Teva Releases Q2 2025 Aide Memoire
• 06.25.2025 - Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

Recent Filings

• 09.12.2025 - 144 Report of proposed sale of securities
• 09.09.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.06.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.01.2025 - 144 Report of proposed sale of securities
• 08.01.2025 - 144 Report of proposed sale of securities
• 07.30.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.30.2025 - 8-K Current report
• 07.30.2025 - EX-99.1 EX-99.1